Clinical Trial Update: A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update describes evaluating emavusertib in combination with an approved Bruton tyrosine kinase inhibitor for chronic lymphocytic leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bruton tyrosine kinase inhibitor
• Emavusertib (emavusertib)

Snippet

Sponsor: Curis, Inc. | Conditions: Chronic Lymphocytic Leukemia, B-cell Malignancies | Phase 2 | Status: RECRUITING